Should You Buy NuScale While It's Below $15?

NuScale Power remains a high-risk, pre-commercialization story despite its NRC-approved SMR design and roughly $900 million in cash and short-term investments. The company reported $31.5 million of 2025 revenue against $355.8 million in net losses, while first-quarter 2026 revenue fell to nearly nothing and a class-action lawsuit is weighing on sentiment. Analysts have turned more cautious, but the stock still has a first-mover advantage if its TVA and Romanian projects progress over the next decade.

Analysis

SMR is a classic “option on execution” setup, but the market is starting to price the option closer to near-expiry. The key second-order effect is that litigation and weak near-term revenue don’t just pressure sentiment; they raise the cost of future commercial adoption because utilities, sovereign counterparties, and financing partners tend to discount vendors with unresolved governance overhangs. That matters more than the headline cash balance, because the real scarce resource here is counterparties willing to sign multi-year, politically visible projects before the technology has multiple bankable reference plants.

The competitive dynamic is shifting toward whoever can turn policy support into supply-chain certainty. OKLO’s supply-chain partnership signals a different path: not necessarily better reactors today, but a more complete commercialization stack that could reduce perceived project risk for end customers. If NuScale cannot convert its pipeline into binding EPC-grade milestones over the next 6-12 months, the first-mover advantage becomes a fading narrative rather than a moat, and the market will likely continue to reward “execution credibility” over pure regulatory approval.

The catalyst tree is asymmetric. Near term, any legal escalation or project delay likely compresses the multiple further because the stock trades on expectations, not earnings; the downside can stay open for quarters even with ample cash. The upside case requires a sequence of de-risking events — lawsuit contained, partner validation, and a financed project moving toward FID — which is a 12-36 month story, not a trading catalyst. Consensus may be underestimating how long capital can ignore a pre-commercial platform once credibility is impaired, even if the underlying technology remains differentiated.

Key Decisions for Investors

• Avoid initiating new long SMR exposure ahead of litigation visibility; the risk/reward is unfavorable over the next 1-3 months because negative legal headlines can reprice the stock faster than operational progress can support it.
• For tactical traders, consider a small long OKLO / short SMR pair over 3-6 months: both are levered to nuclear enthusiasm, but OKLO appears better positioned to benefit from a relative credibility premium if execution-risk dispersion widens.
• If holding SMR for a 12-24 month horizon, use staged entries only on post-event weakness and size as a venture-style position; the payoff is convex, but mark-to-market drawdowns can remain severe until a financed project reaches FID.
• Use SMR call spreads rather than common stock for any bullish expression: upside is tied to discrete de-risking events, while the premium outlay limits damage if litigation or partner slippage extends the pre-revenue period.
• Monitor for a reversal trigger: first signed, fully funded project milestone with clear economics. That would be the point to reassess from speculative hold to more constructive long, since it would validate the commercialization path and compress the litigation discount.